Tesamorelin

Tesamorelin is a 44-residue peptide whose sequence corresponds to native human GHRH (1-44) with an N-terminal trans-3-hexenoic-acid moiety attached to the tyrosine residue at position 1. This N-terminal modification provides resistance to dipeptidyl peptidase IV — the enzyme responsible for rapid degradation of native GHRH — while preserving GHRH-receptor engagement. The molecule binds the GHRH receptor on pituitary somatotrophs, a class B G-protein-coupled receptor that activates Gs-coupled cAMP signaling. Pharmacokinetic descriptors documented in published animal-model investigations include extended plasma residence relative to native GHRH but shorter than albumin-conjugated analogs such as the CJC-1295 DAC variant. Interaction profile in the literature spans cAMP activation in somatotroph cells, pulsatile-versus-sustained agonism investigations, and GHRH-axis feedback-control research. All activity descriptors here are framed as documented in published work.

Experimental domains documented in the published literature include GHRH-receptor binding-affinity studies, structure-activity investigations probing the role of the N-terminal trans-3-hexenoic-acid moiety in DPP-IV resistance, somatotroph-cell cAMP-signaling assays, comparative work alongside native GHRH, sermorelin (GHRH 1-29 analog), and CJC-1295 albumin-conjugated analogs to dissect plasma-residence effects from intrinsic receptor-engagement properties, and feedback-loop modeling in growth-hormone-axis paradigms. Investigators have also characterized Tesamorelin in studies of receptor internalization kinetics and in proteolytic-stability assays comparing it against the native GHRH(1-44) sequence. Use in laboratory research extends to mechanism-elucidation paradigms where the molecule serves as a stabilized GHRH analog reference. The reference standard is supplied for these and equivalent in-vitro and animal-model experimental contexts only, with no associated guidance for human, clinical, or veterinary application.

Each lot is characterized by reverse-phase HPLC for chromatographic purity and by mass spectrometry for molecular-ion confirmation against the C221H366N72O67S empirical formula. Purity is reported as an HPLC-area percentage on the Certificate of Analysis distributed with every lot, alongside the molecular-weight match within instrument tolerance. The N-terminal trans-3-hexenoic-acid modification is confirmed by tandem mass spectrometry when included in the lot's release specification. Peptide content where applicable is determined by amino-acid analysis or nitrogen-content assay following the analytical method specified on the COA. Residual solvent and water content are reported categorically when these parameters are part of the lot's release specification. The COA records the lot identifier, manufacturing date, and analytical method versions used. Researchers requiring batch-level analytical detail should reference the COA distributed with the supplied material.

For laboratory storage, the lyophilized reference standard should be held at −20°C in its sealed, light-protected container until ready for analytical use. Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation on the lyophile. Reconstitution for in-vitro experimental use is typically performed in bacteriostatic water or a researcher-selected buffer compatible with the downstream assay; once reconstituted, store the working solution at 2–8°C and characterize stability in the relevant buffer prior to extended storage. Avoid repeated freeze-thaw cycles of reconstituted material — single-use aliquots are preferred for experiments where peptide integrity is assay-critical. These handling parameters reflect general best-practice for lyophilized peptide reference standards and do not constitute preparation guidance for human or veterinary application.